Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
AssigneeNovartis AG
InventorsGiordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
Life of this patent
Estimating the term…
Abstract
The present disclosure pertains to a pharmaceutical combination comprising (a) an alpha-isoform specific PI3K inhibitor, (b) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor, and (c) an antimetabolite antineoplastic agent; combined preparations and pharmaceutical compositions thereof; the uses of such a combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Claims2
A method for treating a colorectal cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising:
- (a) a compound having the structure of the formula (I)
- or a pharmaceutically acceptable salt thereof,
- (b) a compound having the structure of Formula (II)
- or a pharmaceutically acceptable salt thereof, and
- (c) an antimetabolite antineoplastic agent 5-fluorouracil or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.